NCT00725855View on ClinicalTrials.gov

A Single-Center, Double-Blind (DB) Study of MEM 3454 on P50 Sensory Gating and Mismatch Negativity in Schizophrenia Patients

PHASE2UnknownINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

March 31, 2009

Study Completion Date

April 30, 2009

Conditions
Schizophrenia
Interventions
DRUG

MEM 3454

1 mg dose

DRUG

MEM 3454

5 mg dose

DRUG

MEM 3454

15 mg dose

DRUG

MEM 3454

50 mg dose

DRUG

Placebo for MEM 3454

Placebo dose

Trial Locations (1)

80262

University of Colorado Health Sciences Center, Denver

Sponsors
All Listed Sponsors
collaborator

Hoffmann-La Roche

INDUSTRY

lead

Memory Pharmaceuticals

INDUSTRY